Related Experiment Video
Updated: May 27, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma
Rabindra Kumar Jena1, Trupti Rekha Swain, Sandeep Sadashivrao Kansurkar
1Department of Clinical Hematology, SCB Medical College and Hospital, Cuttack, 753007 Odisha, India. rkjena@msn.com
Abstract:
The chemotherapeutic regimen melphalan, prednisolone, and thalidomide (MPT) is the standard of care for symptomatic multiple myeloma patients who are not eligible for high dose chemotherapy followed by autologous stem cell therapy. Lenalidomide, a newer thalidomide derivative, is 300 times more potent than thalidomide. Combined therapy using melphalan, prednisolone, and lenalidomide (MPL) is very effective with many advantages. We report here one rare adverse effect, i.e., intrahepatic cholestasis related to lenalidomide, in two patients out of a total of 65 newly diagnosed cases of multiple myeloma receiving MPL regimen in our series. As the use of lenalidomide will increase in the future for multiple myeloma and other diseases, clinicians should be aware of this entity.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug toxicity: Idiosyncratic Reactions
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
